{
    "eid": "2-s2.0-84988975003",
    "title": "Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years",
    "cover-date": "2016-08-15",
    "subject-areas": [
        {
            "$": "Immunology and Allergy",
            "@code": "2723"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        }
    ],
    "keywords": [
        "2-dose schedule",
        "Adjuvant System containing 50 ?g 3-O-desacyl-4?-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 ?g Al3+)",
        "AS04",
        "Cell-mediated immunity",
        "Cervical cancer",
        "CMI",
        "Geometric mean antibody titer",
        "GMT",
        "HPV",
        "Human papillomavirus",
        "IgG",
        "Immunogenicity"
    ],
    "authors": [
        "Thanyawee Puthanakit"
    ],
    "citedby-count": 44,
    "ref-count": 40,
    "ref-list": [
        "Human papillomavirus and cervical cancer",
        "Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia",
        "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide",
        "Comparison of two dose and three dose human papillomavirus vaccine schedules: Cost effectiveness analysis based on transmission model",
        "Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant",
        "Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women",
        "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial",
        "Sustained efficacy up to 4\u00b75 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial",
        "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women",
        "Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV Infection",
        "Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials",
        "Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study",
        "Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study",
        "Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study",
        "Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine",
        "Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years",
        null,
        "Comparison of the immunogenicity and safety of Cervarix\u2122 and Gardasil\u00ae human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years",
        "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y",
        "Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis-inactivated Poliovirus Vaccine to Girls and Young Women",
        "Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls",
        "Randomized trial: Immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls",
        "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",
        "Immune responses to human papillomavirus",
        "A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection",
        "Maintenance of serological memory by polyclonal activation of human memory B cells",
        "Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination",
        "Antigen dependent and independent mechanisms that sustain serum antibody levels",
        "Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months",
        "Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine",
        "Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial",
        "Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA trials",
        "Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial",
        "Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination",
        "Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: A cluster randomized noninferiority trial",
        "Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: Results 29 to 32 months after third dose",
        "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9\u201314 years: Results to month 12 from a randomized trial",
        "Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme"
    ],
    "affiliation": [
        {
            "affiliation-city": "Wavre",
            "affilname": "GlaxoSmithKline Pharmaceuticals SA/NV",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Mumbai",
            "affilname": "GlaxoSmithKline Pharmaceuticals Ltd.",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Cheng Hsin General Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taoyuan",
            "affilname": "Chang Gung University College of Medicine",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Milan",
            "affilname": "Universit\u00e0 degli Studi di Milano",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Padua",
            "affilname": "Azienda Ospedale Universit\u00e0 Padova",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Freiburg im Breisgau",
            "affilname": "Universit\u00e4tsklinikum Freiburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Halifax",
            "affilname": "Dalhousie University",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Genoa",
            "affilname": "Scuola di Scienze Mediche e Farmaceutiche, Universit\u00e0 Degli Studi di Genova",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": null,
            "affilname": "Pediatric Office Dr. Med. Michael Horn",
            "affiliation-country": "Czech Republic"
        },
        {
            "affiliation-city": "Sudbury",
            "affilname": "Medicor Research Inc",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Sherbrooke",
            "affilname": "Q and T Research",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Central Laboratory and Vaccination Centre",
            "affiliation-country": "Germany"
        }
    ],
    "funding": []
}